PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2009 | 14 |
| 2010 | 16 |
| 2011 | 27 |
| 2012 | 22 |
| 2013 | 15 |
| 2014 | 19 |
| 2015 | 21 |
| 2016 | 20 |
| 2017 | 16 |
| 2018 | 11 |
| 2019 | 11 |
| 2020 | 25 |
| 2021 | 13 |
| 2022 | 10 |
| 2023 | 6 |
| 2024 | 76 |
| 2025 | 128 |
| 2026 | 96 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"Immunotherapy"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
The potential of CAR T cells in autoimmune diseases.
- Richter J, Krusche M, Haase I, Kötter I, Kröger N.
- Immunotherapy. 2025 Oct 23;17(13):937-952. doi: 10.1080/1750743X.2025.2558348.
- PMCID: PMC12691564
Richter J, et al.Immunotherapy. 2025.PMCID: PMC12691564 -
Efficacy and safety of chimeric antigen receptor T-cell therapy in primary central nervous system lymphoma: a systematic review and meta-analysis.
- Al-Mashdali AF, Abdelraof MO, Kaddoura R, Halfawi AM, Yousif MEM, Abdulgayoom M, Shah AR, Mohamed SF.
- Immunotherapy. 2026 Sep 16;18(11-12):955-968. doi: 10.1080/1750743X.2026.2722553.
- PMCID: PMC13679336
Al-Mashdali AF, et al.Immunotherapy. 2026.PMCID: PMC13679336 -
5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.
- Liu SV, Babel RA, Kao YH, Chirovsky D, Namakydoust A, Velcheti V.
- Immunotherapy. 2025 Oct 17;17(14):1005-1013. doi: 10.1080/1750743X.2025.2569856.
- PMCID: PMC12582088
Liu SV, et al.Immunotherapy. 2025.PMCID: PMC12582088 -
Cost-utility analysis of blinatumomab in pediatric patients with acute lymphoblastic leukemia in Iran.
- Nikakhtar G, Amiri Z, Eghbali A, Fatemi B.
- Immunotherapy. 2025 Oct 15;17(14):1015-1023. doi: 10.1080/1750743X.2025.2572957.
- PMCID: PMC12582091
Nikakhtar G, et al.Immunotherapy. 2025.PMCID: PMC12582091 -
Recombinant GM-CSF drug evaluation review.
- McCarthy J, Boyle N, McCarthy C.
- Immunotherapy. 2025 Oct 14;17(14):983-993. doi: 10.1080/1750743X.2025.2571020.
- PMCID: PMC12582097
McCarthy J, et al.Immunotherapy. 2025.PMCID: PMC12582097 -
Allogeneic CAR-T cell therapy in autoimmune diseases.
- Ma Y, Qin J, Liu M, Du B.
- Immunotherapy. 2025 Oct 14;17(15):1129-1143. doi: 10.1080/1750743X.2025.2572963.
- PMCID: PMC12607299
Ma Y, et al.Immunotherapy. 2025.PMCID: PMC12607299 -
Evaluating the efficacy and safety of tezepelumab in the treatment of chronic rhinosinusitis with nasal polyps.
- Priessnitz J, Jung J, Han JK, Lam KK.
- Immunotherapy. 2025 Oct 14;17(13):903-912. doi: 10.1080/1750743X.2025.2567844.
- PMCID: PMC12691544
Priessnitz J, et al.Immunotherapy. 2025.PMCID: PMC12691544 -
Exploring new treatment strategies for hard-to-treat double-hit and double-expressor lymphomas.
- Kelsten MF, Karmali R.
- Immunotherapy. 2025 Oct 13;17(15):1059-1061. doi: 10.1080/1750743X.2025.2572956.
- PMCID: PMC12607291
Kelsten MF, et al.Immunotherapy. 2025.PMCID: PMC12607291 -
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis.
- Caraballo A, Osorio L, Díez S, Chinchilla C, Álvarez L, Caraballo L, Sánchez J.
- Immunotherapy. 2025 Oct 12;17(14):995-1004. doi: 10.1080/1750743X.2025.2570903.
- PMCID: PMC12582090
Caraballo A, et al.Immunotherapy. 2025.PMCID: PMC12582090 -
How could γδ T cells change the treatment landscape for colorectal cancers?
- Blanco-Domínguez R, Mensurado S.
- Immunotherapy. 2025 Oct 11;17(14):967-970. doi: 10.1080/1750743X.2025.2572962.
- PMCID: PMC12582096
Blanco-Domínguez R, et al.Immunotherapy. 2025.PMCID: PMC12582096